UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~March~~April 1916, 2007

VIRAGEN, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-15823

59-2101668

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer

Identification No.)


865 SW 78^th Avenue, Suite 100, Plantation, Florida		33324
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (954) 233-8746

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.01. Entry into a Material Definitive Agreement

~~Item~~On April 16, 22007, Viragen International, Inc.~~02.~~, ~~Results~~our ofmajority-owned ~~Operations~~subsidiary, ~~and~~entered ~~Financial~~into ~~Condition~~a license agreement with Swedish Orphan International that grants exclusive rights to Swedish Orphan International to market Multiferon® (multi-subtype, human alpha interferon) in the European Union (excluding previously licensed member states).

~~Item~~Under 8the agreement, Viragen International received approximately $2 million (€1.015 million) as an up-front license fee. ~~Other~~During ~~Events~~the term of the agreement, Viragen International will serve as the exclusive manufacturer of the product for Swedish Orphan International, and Swedish Orphan International has agreed not to sell competing products, including alpha interferons, in the exclusive territory. Swedish Orphan International will pay Viragen for Multiferon® at an agreed upon sales price, and, in addition, Viragen will receive double-digit royalties from Swedish Orphan International on their net sales. Unless extended by mutual agreement, the license agreement will terminate ten years following the date of product launch in the last country in the territory covered by the agreement.

OnSwedish ~~March 19,~~Orphan ~~2007~~International ~~Viragen,~~will ~~Inc. completed~~also ancontrol ~~equity-for-debt~~and ~~restructuring~~fund ~~agreement~~a ~~with~~significant ~~seven~~portion ~~institutional~~of ~~investors~~the ~~who~~costs ~~had~~for ~~previously~~a ~~held~~planned ~~approximately~~European $9post-marketing clinical study.2 ~~million~~The post-marketing intrial ~~convertible~~will ~~notes~~further ~~and~~evaluate ~~debentures,~~the asuse ~~well~~of asMultiferon® ~~related~~for ~~warrants~~the first-line adjuvant treatment of high-risk malignant melanoma (Stages IIb-III). The ~~terms~~marketing of ~~this~~Multiferon® ~~debt~~in ~~restructuring~~the European Union (other than in Sweden) will require marketing authorization from applicable regulatory bodies, which is expected to ~~agreement~~be ~~permitted~~sought through the ~~holders~~Mutual Recognition Procedure (MRP) adhered to by a majority of the ~~notes,~~European ~~debentures~~Union’s ~~and~~member ~~related~~states. ~~warrants~~Under tothe ~~immediately~~license ~~exchange~~agreement, ~~those~~Viragen ~~securities~~International is responsible for ~~common~~the ~~shares~~preparation, at its expense, of ~~Viragen.~~the ~~The~~registration dossier ~~exchange~~for ~~was~~submission ~~effected~~under atthe aMRP, ~~rate~~as ofwell ~~one~~as ~~share~~responses ofto ~~common~~additional ~~stock~~requests for ~~each $0~~information.10 ofSwedish ~~outstanding~~Orphan ~~notes and~~International ~~debentures,~~is ~~resulting~~responsible infor the ~~issuance~~filing of ~~approximately~~the ~~93 million~~dossier ~~shares.~~and ~~The~~the ~~amount~~submission of ~~notes,~~additional ~~debentures,~~information ~~interest~~prepared by Viragen International, and ~~warrants~~once ~~tendered~~regulatory ~~for~~authorization ~~exchange~~is byreceived, ~~each~~Swedish ~~debt~~Orphan ~~holder~~International ~~and~~is responsible for maintaining the ~~number~~marketing ofauthorizations, ~~shares~~with ~~issued~~related inexpenses ~~exchange~~to ~~therefore~~be isreimbursed asby ~~follows:~~ Viragen International.

Name of Investor	Principal Amount of DebtExchanged		Accrued But Unpaid InterestExchanged		Number ofWarrantsExchanged	Number of Shares Issued inExchange
Alexandra Global Master Fund Ltd.	$	3,500,000	$	53,764	1,343,854	35,537,639
Alpha Capital AG		500,000		7,680	191,981	5,076,806
Crescent International Limited		653,125		9,217	431,578	6,623,417
Crestview Capital Master, LLC		53,125		—	47,619	531,250
Portside Growth and Opportunity Fund		1,366,467		20,989	—	13,874,561
Rockmore Investment Master Fund Ltd.		633,533		9,733	243,251	6,432,662
Satellite Strategic Finance Associates, LLC		2,450,000		37,635	2,303,748	24,876,348
Total	$	9,156,250	$	139,018	4,562,031	92,952,683

On April 18, 2007, we issued a press release announcing this licensing agreement. The full text of the press release is furnished as Exhibit 99.1 to this report.

As a result of the restructuring of indebtedness, as described above, Viragen’s indebtedness (current and long-term) has been reduced by an aggregate of $9,156,250 and its stockholders’ equity has increased by approximately $8.2 million on a pro forma basis. The following balance sheet presents the actual balance sheet of Viragen as of December 31, 2006, as adjusted solely to give effect to the exchange of equity-for-debt, as described above. The balance sheet is unaudited and, other than with respect to the exchange, does not give effect to results of operations subsequent to December 31, 2006. The balance sheet also does not give effect to other adjustments that may need to be recorded as a result of the reduction in the conversion prices on the Company’s remaining convertible debt and issuance of additional warrants to certain warrant holders that were entitled to additional warrants upon the reduction in the exercise price of their warrants. We expect stockholders’ equity at March 31, 2007 will be less than the amount shown in the December 31, 2006 pro forma balance sheet primarily as a result of operational losses incurred during the quarter ending March 31, 2007.

VIRAGEN, INC. AND SUBSIDIARIES

CONSOLIDATED CONDENSED BALANCE SHEETS

(Unaudited)

	Actual December 31, 2006			Pro FormaDecember 31, 2006
ASSETS
Current assets
Cash and cash equivalents	$	2,343,488		$	2,322,863
Accounts receivable		65,368			65,368
Inventories		664,089			664,089
Prepaid expenses		624,635			624,635
Other current assets		196,389			111,998
Total current assets		3,893,969			3,788,953
Property, plant and equipment
Land, building and improvements		5,130,186			5,130,186
Equipment and furniture		4,309,875			4,309,875
		9,440,061			9,440,061
Less accumulated depreciation		(4,611,816	)		(4,611,816	)
		4,828,245			4,828,245
Goodwill		4,176,265			4,176,265
Developed technology, net		1,574,117			1,574,117
Deposits and other assets		77,288			20,651
	$	14,549,884		$	14,388,231
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Accounts payable	$	988,001		$	988,001
Accrued expenses and other liabilities		1,086,420			901,795
Current portion of convertible notes and debentures		78,034			19,761
Short term borrowings		112,736			112,736
Current portion of long-term debt		73,216			73,216
Total current liabilities		2,338,407			2,095,509
Convertible notes and debentures, less current portion		9,514,303			1,363,762
Long-term debt, less current portion		654,141			654,141
Deferred income tax liability		390,799			390,799
Royalties payable		107,866			107,866
Commitments and contingencies
Stockholders’ equity
Convertible 10% Series A cumulative preferred stock, $1.00 par value. Authorized 375,000 shares; 2,150 shares issued and outstanding at December 31, 2006. Liquidation preference value: $10 per share, aggregating $21,500 at December 31, 2006		2,150			2,150
Common stock, $.01 par value. Authorized 250,000,000 shares; 120,285,104 shares issued and outstanding and 214,360,131 shares (pro forma) issued and outstanding at December 31, 2006		1,202,851			2,143,601
Capital in excess of par value		173,726,307			182,265,450
Accumulated deficit		(177,088,339	)		(178,336,446	)
Accumulated other comprehensive income		3,701,399			3,701,399
Total stockholders’ equity		1,544,368			9,776,154
	$	14,549,884		$	14,388,231

The foregoing balance sheet is being filed in an effort to demonstrate Viragen’s compliance with the continued listing criteria of the American Stock Exchange (AMEX), which had previously provided Viragen with a temporary exception to its continued listing criteria until March 20, 2007, at which time Viragen was required to demonstrate to the AMEX that its stockholders’ equity was at least $6 million, or to otherwise demonstrate that it met the AMEX’s financial criteria for continued listing. Viragen has not yet received confirmation from the AMEX that it now complies with the AMEX’s continued listing criteria. Viragen’s listing status remains subject to review by AMEX and AMEX could determine to delist Viragen’s shares. Additionally, Viragen cannot guarantee its compliance with AMEX listing criteria through subsequent quarters and may be subject to future delisting from AMEX for failing to maintain compliance.

In accordance with the adjustment provisions of outstanding indebtedness and warrants (other than the debt and warrants that have been tendered for exchange), as a result of the rate at which we issued our common stock in the exchange, (a) the conversion rate at which outstanding notes and debentures (other than the notes and debentures tendered in the exchange) in the aggregate principal amount of approximately $1.55 million has been reduced to $0.10 per share, (b) the exercise price of outstanding common stock purchase warrants (other than the common stock purchase warrants surrendered in the exchange) to purchase an aggregate of 5,756,630 shares of common stock was reduced to $0.10 per share and (c) we issued common stock purchase warrants to purchase an aggregate of 46,799,447 shares of common stock at a price of $0.10 per share.

On March 20, 2007, Viragen issued a press release announcing the restructuring of its indebtedness. A copy of that press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01

Financial Statements and Exhibits

(d)

Exhibits.

~~10.1~~	~~Form of Offer to Exchange, including addendum~~10.1	License Agreement between Viragen International, Inc. and Swedish Orphan International AB dated April 16, 2007 (incorporated by reference to Viragen International, Inc.’s Form 8-K dated April 16, 2007 filed with the SEC on April 19, 2007) **
99.1	Press release dated March 20, 2007
	10.2	Safety Agreement between Viragen International, Inc. and Swedish Orphan International AB dated April 16, 2007 (incorporated by reference to Viragen International, Inc.’s Form 8-K dated April 16, 2007 filed with the SEC on April 19, 2007)


		10.3		Technical Agreement between Viragen International, Inc. and Swedish Orphan International AB dated April 16, 2007 (incorporated by reference to Viragen International, Inc.’s Form 8-K dated April 16, 2007 filed with the SEC on April 19, 2007)

		99.1		Press release dated April 18, 2007 *

*	Filed herewith

**	Confidential treatment requested for certain portions of this exhibit pursuant to Rule 24(b)(2) under the Securities Exchange Act of 1934, as amended, which portions are omitted and filed separately with the Securities and Exchange Commission.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	~~VIRAGEN, INC.~~	VIRAGEN, INC.
Date: March 22, 2007	By:	/s/ Dennis W. Healey
Date: April 18, 2007		By:	/s/ Dennis W. Healey
		~~Dennis W. Healey~~	Dennis W. Healey
		Executive Vice President and Principal Financial Officer
			Executive Vice President and
			Principal Financial Officer

INDEX TO EXHIBITS

ExhibitNumber		Description
10.1		Form of Offer to Exchange, including addendum
99.1		Press release dated April 18, 2007
99.1		Press release dated March 20, 2007

Filing Compare · VIRAGEN INC